Inovio Pharma (INO) reported Q1 EPS of ($0.36), $0.02 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $199 thousand versus the consensus estimate of $670 thousand.
As of March 31, 2022, cash and cash equivalents and short-term investments were $360.4 million compared to $401.3 million as of December 31, 2021. As of March 31, 2022, the Company had 226.5 million common shares outstanding and 247.8 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.